GlassScriptPhysician profile
Mayur C Patel
NPI 1669451571
$9,788.96
in general payments reported to CMS, 2019-2025
47 companies · $1,509 in 2025
The $1,509 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,200 · 2020: $724 · 2021: $1,532 · 2022: $1,111 · 2023: $1,881 · 2024: $1,832 · 2025: $1,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,134 · Education: $87.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,134.48 |
| Education | $87.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,563.84 | 2019-2025 | Airsupra, Fasenra, Farxiga |
| Glaxosmithkline, LLC. | $1,425.40 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $875.12 | 2019-2025 | Ofev, Spiriva Respimat, Jardiance |
| Insmed, INC. | $522.90 | 2020-2025 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $475.00 | 2019-2025 | Opsumit, Uptravi |
| Baxter Healthcare | $444.37 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Genzyme Corporation | $325.14 | 2022-2025 | |
| Philips North America LLC | $300.61 | 2019-2024 | (8874) Incourage |
| Galvanize Therapeutics, INC | $288.50 | 2025 | Aliya System |
| Regeneron Healthcare Solutions, INC. | $260.41 | 2021-2024 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $242.10 | 2021-2024 | |
| Pulmonx Corporation | $203.04 | 2022-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Stryker Corporation | $170.36 | 2021 | |
| Pfizer INC. | $167.48 | 2019-2025 | |
| Abbvie INC. | $159.62 | 2023 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $155.98 | 2022-2025 | Smartvest |
| Teva Pharmaceuticals USA, INC. | $154.85 | 2021-2023 | Austedo Xr |
| Penumbra, INC. | $147.52 | 2023 | Indigo System |
| Alexion Pharmaceuticals, INC. | $144.61 | 2021-2025 | Ultomiris |
| Boston Scientific Corporation | $143.91 | 2025 | Farapulse |
| Amgen INC. | $141.45 | 2021-2024 | Repatha |
| Dexcom, INC. | $139.86 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $116.66 | 2021-2024 | |
| Exact Sciences Corporation | $110.50 | 2023-2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $108.58 | 2019-2024 | Yupelri |
| United Therapeutics Corporation | $101.66 | 2022-2023 | Tyvaso, Orenitram |
| E.R. Squibb & Sons, L.L.C. | $87.31 | 2019-2021 | |
| Genentech USA, INC. | $78.28 | 2019-2025 | Tecentriq, Venclexta |
| Grifols USA, LLC | $76.23 | 2021-2024 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $74.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $70.63 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $52.84 | 2024 | Padcev |
| Merck Sharp & Dohme LLC | $50.63 | 2023-2025 | Verquvo, Winrevair |
| Viatris Specialty LLC | $50.61 | 2025 | Yupelri |
| Paratek Pharmaceuticals, INC. | $50.51 | 2024-2025 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $44.13 | 2019 | |
| Acadia Pharmaceuticals INC | $41.69 | 2019-2024 | Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $28.84 | 2022 | |
| Lilly USA, LLC | $28.69 | 2020 | |
| Sun Pharmaceutical Industries INC. | $24.73 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.12 | 2025 | Rexulti |
| Amarin Pharma, INC. | $23.93 | 2019 | |
| Advanced Respiratory, INC | $23.41 | 2021 | |
| Novo Nordisk INC | $21.73 | 2021 | |
| Gilead Sciences, INC. | $18.69 | 2025 | Veklury |
| Inogen, INC. | $13.90 | 2025 | |
| Sk Life Science, INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayur Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.